BRP-39

BRP-39 is a potent and selective small-molecule inhibitor of the **5-lipoxygenase-activating protein (FLAP)**, a critical component in the biosynthesis of pro-inflammatory leukotrienes. Developed by researchers at the **University of Jena** as part of a series of indole-3-yl-propanoic acid derivatives, BRP-39 blocks the production of leukotrienes (such as LTB4 and cysteinyl leukotrienes) by preventing the transfer of arachidonic acid to the 5-lipoxygenase enzyme. It is primarily utilized as a pharmacological research tool to investigate the role of the leukotriene pathway in inflammatory and respiratory diseases, including asthma and cardiovascular conditions. Importantly, the name "BRP-39" is also the standard designation for **Breast Regression Protein 39**, the murine ortholog of the human chitinase-like protein **YKL-40** (CHI3L1). In the context of immunology and respiratory research (as seen in the provided abstract), BRP-39 refers to this endogenous protein, which acts as a regulator of tissue remodeling, extracellular matrix (ECM) turnover, and airway hyperreactivity in conditions like allergic fungal asthma. While the protein itself is not a therapeutic drug, it is a significant biomarker and potential therapeutic target.

Other names

3-[1-(4-chlorobenzyl)-4-methyl-6-(quinolin-2-ylmethoxy)-1H-indol-3-yl]-2,2-dimethylpropanoic acidBreast Regression Protein 39